Moderna (MRNA) ended the recent trading session at $25.90, demonstrating a +1.97% change from the preceding day's closing price. This change outpaced the S&P 500's 0.22% loss on the day. Elsewhere, ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many ...

The epidemiologist and immunologist Michael Mina called Kennedy’s move a “code red” for vaccines in America. None of the ...

President Donald Trump's administration last month canceled a $590-million contract awarded to Moderna in January by outgoing ...

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

A BU professor warns that federal funding cuts, immigration restrictions and housing costs could reshape the region's status ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

In spring training for the 2024 season, the Railroaders were set to have another intra-team scrimmage with Austin Faith taking the mound as one of the starting pitchers. Faith had a weird feeling all ...

Among the eight people who Robert F. Kennedy Jr. announced would make up his new group of outside vaccine advisers to the US Centers for Disease Control and Prevention are an emergency physician who ...

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...